| Source publication date | |
|---|---|
| Reported on Testosterone Science | |
| Outlet type | Medical and professional news |
| Population | Women |
| Source | Contemporary OB/GYN |
| URL | contemporaryobgyn.net/view/fda-holding-public-meeting-on-testosterone-use-in-menopausal-women (opens in a new tab) |
Specific Claim Evaluated
Critical knowledge gaps remain on the effects of testosterone on sexual function, cognition, mood and musculoskeletal health in menopausal women, and no FDA-approved testosterone product exists for women.
Primary Research Supporting or Contradicting the Claim
The global consensus statement finds evidence only for hypoactive sexual desire disorder and insufficient evidence for other outcomes (Davis et al., 2019).
Corrected Evidence-Based Interpretation
The report is correct.
Rationale for Grade
The article reports the FDA position and clinician comments on dosing and compounding accurately, and makes no claim of benefit beyond the evidence.
References
- Davis SR, Baber R, Panay N, Bitzer J, Perez SC, Islam RM, Kaunitz AM, Kingsberg SA, Lambrinoudaki I, Liu J, Parish SJ, Pinkerton J, Rymer J, Simon JA, Vignozzi L, Wierman ME. Global consensus position statement on the use of testosterone therapy for women. J Clin Endocrinol Metab. 2019;104(10):4660-4666. PMID
Supporting excerpt: "The only evidence-based indication for testosterone for women is for HSDD."